Cetuximab and panitumumab for treating RAS wild-type colorectal cancer

Published on 04 Jan 2022
Last Updated on 12 Jul 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Cetuximab 100 mg/20 mL solution for infusion; and

• Panitumumab 100 mg/5 mL concentrate for solution for infusion

as monotherapy or in combination with chemotherapy for treating RAS wild-type metastatic colorectal cancer.

Subsidy status

Panitumumab 100 mg/5 mL concentrate for solution for infusion is recommended for inclusion on the MOH Standard Drug List (SDL) for the abovementioned indication with effect from 4 January 2022.

Cetuximab 100 mg/20 mL solution for infusion is recommended for inclusion on the SDL for the abovementioned indication with effect from 1 September 2022.

Cetuximab and panitumumab for treating RAS wild-type colorectal cancer (Updated 12 Jul 2022) [PDF, 143KB]

PES Treatments for RAS wild type metastatic colorectal cancer (Updated 12 Jul 2022) [PDF, 119 KB]